Quantum BioPharma announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 for Multiple Sclerosis. These studies were commissioned to provide data to support an IND application with the US FDA.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Completes Key Studies for MS Drug Lucid-MS
- Quantum BioPharma Pursues Legal Action Over Alleged Stock Manipulation
- Quantum Group files amended complaint against CIBC, RBC, others
- Quantum BioPharma Schedules Business Update Call for May 6, 2025
- Quantum BioPharma Appoints Kevin Malone to Combat Stock Manipulation